Generex Biotechnology Corp (GNBT):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Generex Biotechnology Corp (GNBT) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C12171
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using its proprietary RapidMist device. Generex through its subsidiary, Antigen Express, has expanded its focus to include immunomedicines incorporating proprietary vaccine formulations for the treatment of infectious, malignant, allergic, and autoimmune diseases. Generex is headquartered in Miramar, Florida, the US.

Generex Biotechnology Corp (GNBT) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Generex Biotechnology Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Generex Biotechnology Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Generex Biotechnology Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Generex Biotechnology Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Generex Biotechnology Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Generex Biotechnology Corp, Medical Equipment, Deal Details 10
Partnerships 10
Generex Biotech Enters into Licensing Agreement with CannScience Innovations 10
Generex Biotech to Enter into Co-Development Agreement with NHTherapeutics 11
Equity Offering 12
Generex Biotec Announces Private Placement Of Units For USD2 Million 12
Generex Biotechnology Raises USD0.8 Million in Private Placement of Series E 9% Convertible Preferred Stock and Warrants 14
Generex Biotechnology Announces Private Placement Of Units For US$1.2 Million 15
Generex Biotech Completes Private Placement Of Units For US$0.8 Million 16
Generex Biotechnology Completes Private Placement Of Units For US$0.75 Million 17
Generex Biotech Completes Private Placement Of Units For US$2 Million 18
Acquisition 20
Generex Biotech to Acquire Remaining 49% Stake in Hema Diagnostic Systems 20
Generex Biotech to Acquire 51% Stake in Regentys 21
Generex Biotech to Acquire 51% Stake in Olaregen Therapeutix 22
Generex Biotech Acquires 51% Interest in Hema Diagnostic Systems for USD15 Million 23
Generex Biotechnology to Acquire 51% Stake in MediTemp for USD5 Million 24
Generex Biotech to Acquire 51% Stake in Alfa Rhythm for USD5 Million 25
Generex Biotechnology Corp – Key Competitors 26
Generex Biotechnology Corp – Key Employees 27
Generex Biotechnology Corp – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Corporate Communications 29
Nov 15, 2018: Generex announces appointment of executive management team 29
Oct 12, 2018: Generex announces Anthony S. Crisci, Esq., CPA as general manager, chief compliance officer and corporate counsel of its new, wholly-owned subsidiary, NuGenerex distribution solutions 31
Jun 25, 2018: Generex Names Terry Thompson As Chief Operating Officer 32
Jan 25, 2017: Yutaka Niihara, MD, MPH, CEO of Emmaus Appointed Executive Chairman of Generex Biotechnology 33
Product News 34
Jul 02, 2018: Generex Biotechnology Announces the Filing of a Patent for its New Diagnostic Point-of-Care Platform, the Express II 34
Other Significant Developments 35
Jan 04, 2018: Generex CEO Provides 2017 Year-End Summary to Stakeholders 35
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Generex Biotechnology Corp, Medical Equipment, Key Facts, 2017 2
Generex Biotechnology Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Generex Biotechnology Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Generex Biotechnology Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Generex Biotechnology Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Generex Biotechnology Corp, Deals By Market, 2012 to YTD 2018 8
Generex Biotechnology Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Generex Biotech Enters into Licensing Agreement with CannScience Innovations 10
Generex Biotech to Enter into Co-Development Agreement with NHTherapeutics 11
Generex Biotec Announces Private Placement Of Units For USD2 Million 12
Generex Biotechnology Raises USD0.8 Million in Private Placement of Series E 9% Convertible Preferred Stock and Warrants 14
Generex Biotechnology Announces Private Placement Of Units For US$1.2 Million 15
Generex Biotech Completes Private Placement Of Units For US$0.8 Million 16
Generex Biotechnology Completes Private Placement Of Units For US$0.75 Million 17
Generex Biotech Completes Private Placement Of Units For US$2 Million 18
Generex Biotech to Acquire Remaining 49% Stake in Hema Diagnostic Systems 20
Generex Biotech to Acquire 51% Stake in Regentys 21
Generex Biotech to Acquire 51% Stake in Olaregen Therapeutix 22
Generex Biotech Acquires 51% Interest in Hema Diagnostic Systems for USD15 Million 23
Generex Biotechnology to Acquire 51% Stake in MediTemp for USD5 Million 24
Generex Biotech to Acquire 51% Stake in Alfa Rhythm for USD5 Million 25
Generex Biotechnology Corp, Key Competitors 26
Generex Biotechnology Corp, Key Employees 27
Generex Biotechnology Corp, Subsidiaries 28

List of Figures
Generex Biotechnology Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Generex Biotechnology Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Generex Biotechnology Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Generex Biotechnology Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Generex Biotechnology Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Generex Biotechnology Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Generex Biotechnology Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Generex Biotechnology Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Generex Biotechnology Corp (GNBT):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Toyota Tsusho Corporation:企業の戦略・SWOT・財務情報
    Toyota Tsusho Corporation - Strategy, SWOT and Corporate Finance Report Summary Toyota Tsusho Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Kubota Corporation (6326):企業の財務・戦略的SWOT分析
    Kubota Corporation (6326) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Amgen Inc (AMGN)-製薬・医療分野:企業M&A・提携分析
    Summary Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncol …
  • Jones Soda Co.:企業の戦略・SWOT・財務情報
    Jones Soda Co. - Strategy, SWOT and Corporate Finance Report Summary Jones Soda Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Innovent Biologics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Innovent Biologics Inc (Innovent Biologics) is a biopharmaceutical company that discovers, develops and manufactures monoclonal antibodies. The company offers monoclonal antibodies such as IBI301, IBI302 and IBI303, among others. Its products are used for the treatment of non-Hodgkin’s lymph …
  • Nando’s Chickenland Limited:企業の戦略的SWOT分析
    Nando's Chickenland Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Celltrion Inc (068270):製薬・医療:M&Aディール及び事業提携情報
    Summary Celltrion Inc (Celltrion) is a biopharmaceutical company that focuses on research, development and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Cr …
  • Fluor Corporation (FLR):企業の財務・戦略的SWOT分析
    Fluor Corporation (FLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Fluidigm Corp (FLDM):企業の財務・戦略的SWOT分析
    Summary Fluidigm Corp (Fluidigm), formerly Mycometrix Corp, develops, manufactures, and markets life science analytical and preparatory systems for mass cytometry, high-throughput genomics, and single-cell genomics markets. The company offers analytical systems and instruments, preparatory instrumen …
  • Brookfield Property REIT Inc (BPYU):企業の財務・戦略的SWOT分析
    Brookfield Property REIT Inc (BPYU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • MRC Systems GmbH:企業の製品パイプライン分析
    Summary MRC Systems GmbH (MRC Systems) is a medical device company that offers medical, electronic and laser optical products. The company’s products include laser beam stabilization, MR compatible cameras, pinprick, cardioman, photoactivation and stereotactic systems. It offers laser beam stabiliza …
  • Primark Stores Ltd:企業の戦略・SWOT・財務情報
    Primark Stores Ltd - Strategy, SWOT and Corporate Finance Report Summary Primark Stores Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • National Shipping Company of Saudi Arabia (4030):石油・ガス:M&Aディール及び事業提携情報
    Summary National Shipping Company of Saudi Arabia (Bahri) is a joint stock shipping company, which purchases, charters and operates shipping vessels for the transportation of crude oil, liquefied petroleum gas (LPG), petrochemicals, general cargo, passengers and dry bulk. It operates a fleet of very …
  • Lava Therapeutics BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Lava Therapeutics BV (Lava Therapeutics) is a biotechnology company which develops immune oncology biopharmaceuticals products. Its proprietary V?9Vd2 T-cell engager candidates bind to the conserved (monomorphic) T-cell receptor of V?9Vd2 T-cells which exhibit potent cytotoxicity, interferon …
  • Helius Medical Technologies Inc (HSM):医療機器:M&Aディール及び事業提携情報
    Summary Helius Medical Technologies Inc (HMT) is a medical device company that provides neurological wellness solutions. The company provides development, licensing and acquisition of non-invasive platform technologies for amplifying the brain’s ability to heal itself. It provides development of tec …
  • Synchrony Financial
    Synchrony Financial - Strategy, SWOT and Corporate Finance Report Summary Synchrony Financial - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Axel Springer SE:企業の戦略・SWOT・財務情報
    Axel Springer SE - Strategy, SWOT and Corporate Finance Report Summary Axel Springer SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Acerinox Group:企業の戦略・SWOT・財務情報
    Acerinox Group - Strategy, SWOT and Corporate Finance Report Summary Acerinox Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Five Star Senior Living Inc (FVE):企業の財務・戦略的SWOT分析
    Summary Five Star Senior Living Inc (Five Star), formerly Five Star Quality Care Inc is a healthcare service provider that offers senior living and patient care services. The center’s services include independent living, assisted living, skilled nursing care, memory care, dining and nutrition, hospi …
  • The Charles Schwab Corporation:戦略・SWOT・企業財務分析
    The Charles Schwab Corporation - Strategy, SWOT and Corporate Finance Report Summary The Charles Schwab Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆